BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT)

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

205

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

July 31, 2014

Study Completion Date

September 30, 2014

Conditions
Primary Fibromyalgia
Interventions
DRUG

TNX-102 SL 2.8mg

Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.

DRUG

Placebo

Patients will take 1 tablet of randomly assigned study drug sublingually each day at bedtime starting on Day 0 for 12 weeks.

Trial Locations (17)

17055

1001 South Market Street, Mechanicsburg

21702

71 Thomas Johnson Drive, Frederick

29650

322 Memorial Drive, Greer

32806

100 West Gore Street, Orlando

34601

16176 Cortez Boulevard, Brooksville

39202

CRC of Jackson, LLC, Jackson

43212

1275 Olentangy River Road, Columbus

44130

18660 Bagley Road, Middleburg Heights

45219

University of Cincinnati College of Medicine, Cincinnati

60634

3401 North Central Avenue, Chicago

80239

Radiant Research, Inc., Denver

84102

1002 E. South Temple, Salt Lake City

95825

107 Scripps Drive, Sacramento

98007

1951 152nd Place NE, Bellevue

98122

601 Broadway, Seattle

02747

370 Faunce Corner Road, North Dartmouth

01605

Clinical Pharmacology Study Group, Worcester

All Listed Sponsors
lead

Tonix Pharmaceuticals, Inc.

INDUSTRY

NCT01903265 - BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT) | Biotech Hunter | Biotech Hunter